We evaluated the impact of the COVID-19 pandemic on anti-VEGF treatment in ophthalmology patients in a single hospital in northern China. A total of 93 anti-VEGF injections were administered to 85 eyes of 72 patients at The China Medical University First Hospital Department of Ophthalmology during the COVID-19 pandemic. Compared to the same period in 2019, the number of injections decreased by 70%. Fifty-nine eyes of 46 patients were receiving 3+PRN anti-VEGF treatment prior to the outbreak of the COVID-19 pandemic; all of these patients experienced treatment interruptions due to COVID-19-associated reasons. Anatomic and functional outcomes suggest that patients with anti-VEGF treatment interruptions are at risk for severe adverse visual sequelae. Moreover, deferred anti-VEGF treatment due to patient-related or department-related reasons during the COVID-19 pandemic may result in poor visual outcomes for new patients. Our results suggest that COVID-19 has had a significant negative effect on anti-VEGF treatment in ophthalmology patients. Detailed guidance from global experts in ophthalmology is highly sought-after in these challenging circumstances.
展开▼
